UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 377

Sortiert nach

Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population

Transfusion (Philadelphia, Pa.), 2002-08, Vol.42 (8), p.975-979

2002

Volltextzugriff (PDF)

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

Transfusion (Philadelphia, Pa.), 2003-06, Vol.43 (6), p.721-729

2003

Volltextzugriff (PDF)

Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections

ISBT science series, 2014-07, Vol.9 (1), p.30-36

Stramer, S. L.

2014

Volltextzugriff (PDF)

Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors

Transfusion (Philadelphia, Pa.), 2006-02, Vol.46 (2), p.272-277

2006

Volltextzugriff (PDF)

Infectious disease agents and their potential threat to transfusion safety (an update to the 2009 Transfusion supplement)

Transfusion (Philadelphia, Pa.), 2024-02, Vol.64 (S1), p.S1-S3

2024

Volltextzugriff (PDF)

New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes

JAMA : the journal of the American Medical Association, 1998-07, Vol.280 (1), p.42

1998

Volltextzugriff (PDF)

Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV

Transfusion (Philadelphia, Pa.), 2004-02, Vol.44 (2), p.275-281

2004

Volltextzugriff (PDF)

In Vitro Evaluation of the Protective Role of Human Antibodies to West Nile Virus (WNV) Produced during Natural WNV Infection

The Journal of infectious diseases, 2008-11, Vol.198 (9), p.1300-1308

2008

Volltextzugriff (PDF)

Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004

Transfusion (Philadelphia, Pa.), 2006-05, Vol.46 (5), p.703-707

2006

Volltextzugriff (PDF)

Cytokine and Chemokine Responses in the Acute Phase of Hepatitis B Virus Replication in Naive and Previously Vaccinated Blood and Plasma Donors

The Journal of infectious diseases, 2014-03, Vol.209 (6), p.845-854

2014

Volltextzugriff (PDF)

Transmission of West Nile Virus through Blood Transfusion in the United States in 2002

The New England journal of medicine, 2003-09, Vol.349 (13), p.1236-1245

2003

Volltextzugriff (PDF)

Viral diagnostics in the arena of blood donor screening

Vox sanguinis, 2004-07, Vol.87 (s2), p.180-183

Stramer, S. L.

2004

Volltextzugriff (PDF)

Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing

The New England journal of medicine, 2004-08, Vol.351 (8), p.760-768

2004

Volltextzugriff (PDF)

Reacting to an emerging safety threat: West Nile virus in North America

Developments in biologicals, 2007, Vol.127, p.43

Stramer, S L

2007

Volltextzugriff (PDF)

Trypanosoma cruzi screening in Texas blood donors, 2008–2012

Epidemiology and infection, 2016-04, Vol.144 (5), p.1010-1013

2016

Volltextzugriff (PDF)

Probability of Viremia with HBV, HCV, HIV, and HTLV among Tissue Donors in the United States

The New England journal of medicine, 2004-08, Vol.351 (8), p.751-759

2004

Volltextzugriff (PDF)

West Nile virus infections projected from blood donor screening data, United States, 2003

Emerging infectious diseases, 2006-03, Vol.12 (3), p.395-402

2006

Volltextzugriff (PDF)

Performance of ORTHO® HCV core antigen and trak-C™ assays for detection of viraemia in pre-seroconversion plasma and whole blood donors

Vox sanguinis, 2005-11, Vol.89 (4), p.201-207

2005

Volltextzugriff (PDF)

Sensitivity and specificity of human T-lymphotropic virus (HTLV) types I and II polymerase chain reaction and several serologic assays in screening a population with a high prevalence of HTLV-II

Transfusion (Philadelphia, Pa.), 1999-11, Vol.39 (11), p.1185-1193

1999

Volltextzugriff (PDF)

NAT update: where are we today?

Developments in biologicals, 2002, Vol.108, p.41

Stramer, S L

2002

Volltextzugriff (PDF)

Advances in testing technology to ensure transfusion safety - NAT and beyond

ISBT science series, 2015-04, Vol.10 (S1), p.55-64

2015

Volltextzugriff (PDF)

Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays : justification and rational implementation

Transfusion (Philadelphia, Pa.), 2000, Vol.40 (1), p.15-17

2000

Volltextzugriff (PDF)

Early detection of antibody to human immunodeficiency virus type 1 by using an antigen conjugate immunoassay correlates with the presence of immunoglobulin M antibody

Journal of Clinical Microbiology, 1992-09, Vol.30 (9), p.2379-2384

1992

Volltextzugriff (PDF)

NAT of the United States and Canadian blood supply

Transfusion (Philadelphia, Pa.), 2000-10, Vol.40 (10), p.1165-1168

2000

Volltextzugriff (PDF)

US NAT yield: where are we after 2 years?

Transfusion medicine (Oxford, England), 2002-08, Vol.12 (4), p.243-253

Stramer, S. L.

2002

Volltextzugriff (PDF)

1 – 25 von 377

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(357)
Mit Volltextzugriff
(362)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(271)
Life Sciences & Biomedicine
(262)
Humans
(225)
Blood Donors
(160)
Hematology
(158)
Infectious Diseases
(95)
Male
(90)
Biological And Medical Sciences
(86)
Blood & Organ Donations
(85)
Female
(82)
Medical Sciences
(82)
Adult
(65)
Infections
(60)
Blood
(57)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(55)
Transfusions. Complications. Transfusion Reactions. Cell And Gene Therapy
(55)
Middle Aged
(53)
Viral Diseases
(52)
Blood Transfusion
(49)
Immunology
(48)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections

Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors

Infectious disease agents and their potential threat to transfusion safety (an update to the 2009 Transfusion supplement)

New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes

Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV

In Vitro Evaluation of the Protective Role of Human Antibodies to West Nile Virus (WNV) Produced during Natural WNV Infection

Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004

Cytokine and Chemokine Responses in the Acute Phase of Hepatitis B Virus Replication in Naive and Previously Vaccinated Blood and Plasma Donors

Transmission of West Nile Virus through Blood Transfusion in the United States in 2002

Viral diagnostics in the arena of blood donor screening

Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing

Reacting to an emerging safety threat: West Nile virus in North America

Trypanosoma cruzi screening in Texas blood donors, 2008–2012

Probability of Viremia with HBV, HCV, HIV, and HTLV among Tissue Donors in the United States

West Nile virus infections projected from blood donor screening data, United States, 2003

Performance of ORTHO® HCV core antigen and trak-C™ assays for detection of viraemia in pre-seroconversion plasma and whole blood donors

Sensitivity and specificity of human T-lymphotropic virus (HTLV) types I and II polymerase chain reaction and several serologic assays in screening a population with a high prevalence of HTLV-II

NAT update: where are we today?

Advances in testing technology to ensure transfusion safety - NAT and beyond

Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays : justification and rational implementation

Early detection of antibody to human immunodeficiency virus type 1 by using an antigen conjugate immunoassay correlates with the presence of immunoglobulin M antibody

NAT of the United States and Canadian blood supply

US NAT yield: where are we after 2 years?

Suchergebnisse filtern